TY - JOUR
T1 - The impact of COVID-19 restrictions on participant enrollment in the PREPARE trial
AU - Pogorzelski, David
AU - McKay, Paula
AU - Weaver, Michael J.
AU - Jaeblon, Todd
AU - Hymes, Robert A.
AU - Gaski, Greg E.
AU - Fraifogl, Joanne
AU - Ahn, James S.
AU - Bzovsky, Sofia
AU - Slobogean, Gerard
AU - Sprague, Sheila
AU - Slobogean, Gerard P.
AU - Wells, Jeffrey
AU - Bhandari, Mohit
AU - O'Toole, Robert V.
AU - D'Alleyrand, Jean Claude
AU - Eglseder, Andrew
AU - Johnson, Aaron
AU - Langhammer, Christopher
AU - Lebrun, Christopher
AU - Nascone, Jason
AU - Pensy, Raymond
AU - Pollak, Andrew
AU - Sciadini, Marcus
AU - Degani, Yasmin
AU - Demyanovich, Haley K.
AU - Howe, Andrea
AU - O'Hara, Nathan N.
AU - Phipps, Heather
AU - Hempen, Eric
N1 - Publisher Copyright:
© 2022
PY - 2022/10
Y1 - 2022/10
N2 - Background: At the initiation of the COVID-19 pandemic, restrictions forced researchers to decide whether to continue their ongoing clinical trials. The PREPARE (Pragmatic Randomized Trial Evaluating Pre-Operative Alcohol Skin Solutions in Fractured Extremities) trial is a pragmatic cluster-randomized crossover trial in patients with open and closed fractures. PREPARE was enrolling over 200 participants per month at the initiation of the pandemic. We aim to describe how the COVID-19 research restrictions affected participant enrollment. Methods: The PREPARE protocol permitted telephone consent, however, sites were obtaining consent in-person. To continue enrollment after the initiation of the restrictions participating sites obtained ethics approval for telephone consent scripts and the waiver of a signature on the consent form. We recorded the number of sites that switched to telephone consent, paused enrollment, and the length of the pause. We used t-tests to compare the differences in monthly enrollment between July 2019 and November 2020. Results: All 19 sites quickly implement telephone consent. Fourteen out of nineteen (73.6%) sites paused enrollment due to COVID-19 restrictions. The median length of enrollment pause was 46.5 days (range, 7–121 days; interquartile range, 61 days). The months immediately following the implementation of restrictions had significantly lower enrollment. Conclusion: A pragmatic design allowed sites to quickly adapt their procedures for obtaining informed consent via telephone and allowed for minimal interruptions to enrollment during the pandemic.
AB - Background: At the initiation of the COVID-19 pandemic, restrictions forced researchers to decide whether to continue their ongoing clinical trials. The PREPARE (Pragmatic Randomized Trial Evaluating Pre-Operative Alcohol Skin Solutions in Fractured Extremities) trial is a pragmatic cluster-randomized crossover trial in patients with open and closed fractures. PREPARE was enrolling over 200 participants per month at the initiation of the pandemic. We aim to describe how the COVID-19 research restrictions affected participant enrollment. Methods: The PREPARE protocol permitted telephone consent, however, sites were obtaining consent in-person. To continue enrollment after the initiation of the restrictions participating sites obtained ethics approval for telephone consent scripts and the waiver of a signature on the consent form. We recorded the number of sites that switched to telephone consent, paused enrollment, and the length of the pause. We used t-tests to compare the differences in monthly enrollment between July 2019 and November 2020. Results: All 19 sites quickly implement telephone consent. Fourteen out of nineteen (73.6%) sites paused enrollment due to COVID-19 restrictions. The median length of enrollment pause was 46.5 days (range, 7–121 days; interquartile range, 61 days). The months immediately following the implementation of restrictions had significantly lower enrollment. Conclusion: A pragmatic design allowed sites to quickly adapt their procedures for obtaining informed consent via telephone and allowed for minimal interruptions to enrollment during the pandemic.
KW - COVID-19
KW - Enrollment
KW - PREPARE trial
KW - Pragmatic trials
UR - http://www.scopus.com/inward/record.url?scp=85136256140&partnerID=8YFLogxK
U2 - 10.1016/j.conctc.2022.100973
DO - 10.1016/j.conctc.2022.100973
M3 - Article
AN - SCOPUS:85136256140
SN - 2451-8654
VL - 29
JO - Contemporary Clinical Trials Communications
JF - Contemporary Clinical Trials Communications
M1 - 100973
ER -